Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 5/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clorprenaline SCHEMBL29483933 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| Clorprenaline SCHEMBL406791 | 0.98 | ADRB2 (0.97) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| Clorprenaline SCHEMBL30394245 | 0.98 | ADRB2 (0.97) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| Clorprenaline SCHEMBL29417577 | 0.97 | ADRB2 (0.93) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| Clorprenaline SCHEMBL2852861 | 0.97 | ADRB2 (0.93) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| Clorprenaline SCHEMBL15568417 | 0.97 | ADRB2 (0.93) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| Clorprenaline SCHEMBL45370 | 0.97 | ADRB2 (0.93) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| Clorprenaline SCHEMBL2852860 | 0.95 | ADRB2 (0.90) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| Clorprenaline SCHEMBL1650012 | 0.95 | ADRB2 (0.90) | ADRB2ADRB1CYP2D6HIF1ANFKB1 | |
| Clorprenaline SCHEMBL122700 | 0.92 | ADRB2 (0.85) | ADRB2ADRB1CYP2D6HIF1ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1536 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LTD (AU) | 2025-01-16 | — | — | US | claimed |
| CN-119233997-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2024-12-31 | — | — | CN | claimed |
| US-20240398729-A1 | Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | US | claimed |
| EP-4463485-A2 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2024-11-20 | — | — | EP | claimed |
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | claimed |
| WO-2023137373-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| WO-2023137387-A2 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| US-20230220116-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-13 | — | — | US | claimed |
| US-20230220115-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-13 | — | — | US | claimed |
| EP-4178615-A1 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2023-05-17 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| CN-1170356-A | Aerosol drug formulations | ASTRA AB (SE) | 1998-01-14 | — | — | CN | claimed |
| US-5684018-A | Acyloxyisopropyl carbamates as prodrugs for amine drugs | MERCK & CO., INC. (US) | 1997-11-04 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| US-5626854-A | XANTHINE OR B-ADRENERGIC STIMULANT | KAO CORPORATION (JP) | 1997-05-06 | — | — | US | claimed |
| EP-0523537-B1 | Transdermal therapeutic system for the administration of drugs having bronchodilating activity | ZAMBON SPA (IT) | 1996-12-27 | — | — | EP | claimed |
| WO-1996018605-A1 | ACYLOXYISOPROPYL CARBAMATES AS PRODRUGS FOR AMINE DRUGS | MERCK & CO., INC. (US) | 1996-06-20 | — | — | WO | claimed |
| US-5312627-A | Polymer matrix with drugs with bronchodilator agents | ZAMBON GROUP S.P.A. (IT) | 1994-05-17 | — | — | US | claimed |
| EP-0523537-A1 | Transdermal therapeutic system for the administration of drugs having bronchodilating activity | ZAMBON GROUP S.p.A. (IT) | 1993-01-20 | — | — | EP | claimed |
| US-4153677-A | MICROENCAPSULATED BRONCHODILATOR AGENT, ETHYL CELLULOSE FILM | STERLING DRUG INC. (US) | 1979-05-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | ARRB1, ADRB2, ADRB1 | ADRB2 2/4885ADRB1 3/4885CYP2D6 2031/4885 |
| US-20230220115-A1 | TETRAHEDRAL ANTIBODIES | FCGR3B, FCGR2A, FCGR1A | ADRB2 4833/4885ADRB1 4801/4885CYP2D6 4821/4885 |
| US-20230220116-A1 | TETRAHEDRAL ANTIBODIES | FCGR3B, FCGR2A, FCGR1A | ADRB2 4833/4885ADRB1 4801/4885CYP2D6 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.